Although the combination of cisplatin and PARP inhibitors has been evaluated in several types of cancer cells [18,19], to the best of our knowledge, it has not been evaluated in cells derived from oral cancers in vitro or in vivo. Here, PARP1 is linked to lip and oral cavity carcinoma.